These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 26251289)

  • 1. Enhancing Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: Cotargeting Signaling Pathways.
    Johnston SR
    J Natl Cancer Inst; 2015 Oct; 107(10):. PubMed ID: 26251289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer.
    Jerusalem G; Bachelot T; Barrios C; Neven P; Di Leo A; Janni W; de Boer R
    Cancer Treat Rev; 2015 Feb; 41(2):94-104. PubMed ID: 25575443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment algorithms for hormone receptor-positive advanced breast cancer: going forward in endocrine therapy—overcoming resistance and introducing new agents.
    Johnston SR; Schiavon G
    Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Better Together: Targeted Combination Therapies in Breast Cancer.
    Zanardi E; Bregni G; de Braud F; Di Cosimo S
    Semin Oncol; 2015 Dec; 42(6):887-95. PubMed ID: 26615133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endocrine treatment in breast cancer: Cure, resistance and beyond.
    Tryfonidis K; Zardavas D; Katzenellenbogen BS; Piccart M
    Cancer Treat Rev; 2016 Nov; 50():68-81. PubMed ID: 27643748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of drug resistance in relation to site of metastasis: Meta-analyses of randomized controlled trials in advanced breast cancer according to anticancer strategy.
    Niraula S; Ocana A
    Cancer Treat Rev; 2016 Nov; 50():168-174. PubMed ID: 27693931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2- Advanced Breast Cancer.
    Pritchard KI; Chia SK; Simmons C; McLeod D; Paterson A; Provencher L; Rayson D
    Oncologist; 2017 Jan; 22(1):12-24. PubMed ID: 27864574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancing the efficacy of hormonal agents with selected targeted agents.
    Johnston SR
    Clin Breast Cancer; 2009 Jun; 9 Suppl 1():S28-36. PubMed ID: 19561004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endocrine therapy for hormone treatment-naïve advanced breast cancer.
    Martin M; Lopez-Tarruella S; Gilarranz YJ
    Breast; 2016 Aug; 28():161-6. PubMed ID: 27326977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
    Baselga J; Semiglazov V; van Dam P; Manikhas A; Bellet M; Mayordomo J; Campone M; Kubista E; Greil R; Bianchi G; Steinseifer J; Molloy B; Tokaji E; Gardner H; Phillips P; Stumm M; Lane HA; Dixon JM; Jonat W; Rugo HS
    J Clin Oncol; 2009 Jun; 27(16):2630-7. PubMed ID: 19380449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-targeting estrogen receptor and HER2 pathways in breast cancer.
    Mehta A; Tripathy D
    Breast; 2014 Feb; 23(1):2-9. PubMed ID: 24176518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endocrine therapy for advanced/metastatic breast cancer.
    Schiavon G; Smith IE
    Hematol Oncol Clin North Am; 2013 Aug; 27(4):715-36, viii. PubMed ID: 23915741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of palbociclib in combination with letrozole or fulvestrant with endocrine therapies for advanced/metastatic breast cancer: network meta-analysis.
    Chirila C; Mitra D; Colosia A; Ling C; Odom D; Iyer S; Kaye JA
    Curr Med Res Opin; 2017 Aug; 33(8):1457-1466. PubMed ID: 28463012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer.
    Bertelli G; Garrone O; Merlano M; Occelli M; Bertolotti L; Castiglione F; Pepi F; Fusco O; Del Mastro L; Leonard RC
    Oncology; 2005; 69(6):471-7. PubMed ID: 16410685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety in older patient subsets in studies of endocrine monotherapy versus combination therapy in patients with HR+/HER2- advanced breast cancer: a review.
    Freedman RA; Tolaney SM
    Breast Cancer Res Treat; 2018 Feb; 167(3):607-614. PubMed ID: 29103175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [BOLERO -- another remarkable step in treatment of breast cancer].
    Rubovszky G; Láng I
    Magy Onkol; 2014 Jun; 58(2):128-32. PubMed ID: 25010761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Neoadjuvant endocrine therapy for locally advanced breast cancer].
    Viola G; Sergi D; Conti F; Lopez M
    Clin Ter; 2007; 158(5):441-52. PubMed ID: 18062352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment algorithms for hormone receptor-positive advanced breast cancer: applying the results from recent clinical trials into daily practice—insights, limitations, and moving forward.
    Wilson S; Chia SK
    Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exemestane as first-line therapy in postmenopausal women with recurrent or metastatic breast cancer.
    Glück S
    Am J Clin Oncol; 2010 Jun; 33(3):314-9. PubMed ID: 19730353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of inhibitors of mammalian target of rapamycin in the treatment of luminal breast cancer.
    Ciruelos E; Cortes-Funes H; Ghanem I; Manso L; Arteaga C
    Anticancer Drugs; 2013 Sep; 24(8):769-80. PubMed ID: 23838677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.